Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Poster presentation

Unc93 homolog B1 restricts systemic lethal inflammation by orchestrating TLR7 and TLR9 response

Authors: Ryutaro Fukui, Shin-Ichiroh Saitoh, Atsuo Kanno, Masahiro Onji, Takuma Shibata, Akihiko Ito, Morikazu Onji, Mitsuru Matsumoto, Shizuo Akira, Nobuaki Yoshida, Kensuke Miyake

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

Nucleotide sensing-TLRs (Toll-like receptors) recognize pathogen derived-nucleic acids and trigger immune response [1]. Because of the highly conserved structure of nucleic acids, these TLRs have risk to recognize host derived-nucleic acids and induce autoimmune disease, therefore it is important to clarify the mechanisms and control the response. …
Literature
1.
go back to reference Blasius AL, Beutler B: Intracellular toll-like receptors. Immunity. 2010, 32: 305-315. 10.1016/j.immuni.2010.03.012.CrossRefPubMed Blasius AL, Beutler B: Intracellular toll-like receptors. Immunity. 2010, 32: 305-315. 10.1016/j.immuni.2010.03.012.CrossRefPubMed
2.
go back to reference Fukui R, Saitoh S, Matsumoto F, Kozuka-Hata H, Oyama M, Tabeta K, Beutler B, Miyake K: Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med. 2009, 206: 1339-1350. 10.1084/jem.20082316.PubMedCentralCrossRefPubMed Fukui R, Saitoh S, Matsumoto F, Kozuka-Hata H, Oyama M, Tabeta K, Beutler B, Miyake K: Unc93B1 biases Toll-like receptor responses to nucleic acid in dendritic cells toward DNA- but against RNA-sensing. J Exp Med. 2009, 206: 1339-1350. 10.1084/jem.20082316.PubMedCentralCrossRefPubMed
3.
go back to reference Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, Mudd S, Mann N, Sovath S, Goode J, et al: The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol. 2006, 7: 156-164.CrossRefPubMed Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, Crozat K, Mudd S, Mann N, Sovath S, Goode J, et al: The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol. 2006, 7: 156-164.CrossRefPubMed
4.
go back to reference Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S: Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006, 312: 1669-1672. 10.1126/science.1124978.CrossRefPubMed Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S: Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science. 2006, 312: 1669-1672. 10.1126/science.1124978.CrossRefPubMed
5.
go back to reference Santiago-Raber ML, Kikuchi S, Borel P, Uematsu S, Akira S, Kotzin BL, Izui S: Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol. 2008, 181: 1556-1562.CrossRefPubMed Santiago-Raber ML, Kikuchi S, Borel P, Uematsu S, Akira S, Kotzin BL, Izui S: Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus. J Immunol. 2008, 181: 1556-1562.CrossRefPubMed
6.
go back to reference Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, et al: Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 2008, 319: 624-627. 10.1126/science.1150110.CrossRefPubMed Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, et al: Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 2008, 319: 624-627. 10.1126/science.1150110.CrossRefPubMed
7.
go back to reference Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, Flavell RA, Bolland S: Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 2007, 27: 801-810. 10.1016/j.immuni.2007.09.009.PubMedCentralCrossRefPubMed Deane JA, Pisitkun P, Barrett RS, Feigenbaum L, Town T, Ward JM, Flavell RA, Bolland S: Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity. 2007, 27: 801-810. 10.1016/j.immuni.2007.09.009.PubMedCentralCrossRefPubMed
8.
go back to reference Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Su B, Nestle FO, Zal T, et al: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007, 449: 564-569. 10.1038/nature06116.CrossRefPubMed Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Su B, Nestle FO, Zal T, et al: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007, 449: 564-569. 10.1038/nature06116.CrossRefPubMed
9.
go back to reference Fukui R, Saitoh SI, Kanno A, Onji M, Shibata T, Ito A, Matsumoto M, Akira S, Yoshida N, Miyake K: Unc93B1 restricts systemic lethal inflammation by orchestrating toll-like receptor 7 and 9 trafficking. Immunity. 2011 Fukui R, Saitoh SI, Kanno A, Onji M, Shibata T, Ito A, Matsumoto M, Akira S, Yoshida N, Miyake K: Unc93B1 restricts systemic lethal inflammation by orchestrating toll-like receptor 7 and 9 trafficking. Immunity. 2011
Metadata
Title
Unc93 homolog B1 restricts systemic lethal inflammation by orchestrating TLR7 and TLR9 response
Authors
Ryutaro Fukui
Shin-Ichiroh Saitoh
Atsuo Kanno
Masahiro Onji
Takuma Shibata
Akihiko Ito
Morikazu Onji
Mitsuru Matsumoto
Shizuo Akira
Nobuaki Yoshida
Kensuke Miyake
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3619

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.